Plain-English translation of NCT06979362 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new experimental medication designed to help people with a specific type of heart failure called heart failure with preserved ejection fraction — a condition where the heart's pumping chambers become thickened and stiff. Researchers want to see if this medication can reverse or improve the thickening and help the heart work better. You would receive the medication (or a placebo) as an intravenous infusion once every four weeks for about one year, while continuing your regular heart failure medications.
Many people with this type of heart failure don't have good treatment options, and their symptoms can get worse over time. This trial aims to find out whether this new treatment could help improve heart structure and reduce symptoms in people living with this challenging condition.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will visit the research site regularly over about 60 weeks (roughly 14 months). You will receive intravenous infusions of either the new medication or placebo once every four weeks for 48 weeks — this means about 12 infusions total. You'll continue taking all your regular heart failure medications as prescribed. The research team will monitor your heart health through blood tests and heart imaging (like echocardiograms) to see how the treatment is working.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
United States